Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02585934 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
A Phase 3 study, sponsored by Axovant Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,315
- Enrollment target
NCT02585934: Completed Phase 3 study, sponsored by Axovant Sciences.
NCT02585934 is a Phase 3 study that has completed, run by Axovant Sciences. The registered enrollment target is 1,315 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02585934, a Phase 3 study, has completed, sponsored by Axovant Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,315 participants
- Enrollment target
Study Summary
This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
Primary Outcome
The 11-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech. The ADAS-Cog-11 total score range is from 0 to 70, with a higher score indicating more severe cognitive impairment.
Interventions
- DRUG Placebo
- DRUG RVT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,315 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-09 |
| Phase | Phase 3 |
What the finished NCT02585934 record still lists
NCT02585934 is an interventional study that assigns participants to a tested intervention. Its 1,315 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02585934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02585934 about?
NCT02585934 is a clinical study titled "Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study". This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
What is the current status of trial NCT02585934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,315 participants. The study started on 2015-10. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02585934?
The interventions under investigation include: Placebo (DRUG), RVT-101 (DRUG).
Who is sponsoring clinical trial NCT02585934?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02585934's enrollment target sits among peer trials
1,315 185th of 2000 higher than 1,816 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05762302 · 1,316 participants · NA
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia